DC66529 |
ALC-0315 analogue-1 |
ALC-0315 analogue-1 (compound P-10) is a cationic lipid. ALC-0315 analogue-1 is the raw material for synthesis of cationic liposome. |
|
DC60619 |
12T-O14 |
|
|
DC60632 |
Lipid TG6A |
TG6A is a biodegradable and ionizable glycerolipid for cmRNA delivery. TG6A-LNP exhibits above 9-fold and 41-fold higher EGFP protein expression in MSCs than DLin-MC3-DMA-LNP and ALC-0315-LNP, respectively. |
|
DC82210 |
A1-D1-5 |
Lipid A1-D1-5 is an ionizable lipid-like substance used for RNA interference therapy in heat-stable ionizable lipid-like nanoparticles (iLAND) for the treatment of hyperlipidemia. |
|
DC60636 |
Acid-degradable Cationic Lipid (ADC)
Featured
|
Acid-degradable Cationic Lipid (ADC) composed of cationic lipid is synthesized with the azido-acetal linker and used to generate RD-LNPs, which significantly improves the performance of LNP-mRNA complexes in vitro and in vivo. |
|
DC60639 |
Acid-degradable Anionic Lipid (ADA)
Featured
|
ADA (Acid-Degradable Anionic Lipids) is revolutionizing mRNA delivery with its unique azido-acetal linker, enabling rapid hydrolysis in endosomes (pH ~6.0). This breakthrough technology ensures efficient endosomal escape, significantly enhancing mRNA delivery to target cells. ADA-LNPs excel in delivering mRNA to the spleen and liver, making them ideal for immune-related therapies.By degrading into biocompatible byproducts, ADA minimizes long-term tissue persistence and toxicity.ADA-LNPs outperform traditional LNPs, delivering mRNA more effectively to immune cells like macrophages and B cells. |
|
DC66648 |
CP-LC-1143
Featured
|
Lipid CP-LC-1143 is an ionizable cationic amino lipid derived from homocysteine, a naturally occurring amino acid. This lipid has demonstrated an efficient delivery and high protein expression of different kinds of RNA (mRNA, cRNA and saRNA) in vivo, with no signs of toxicity. |
|
DC66649 |
CP-LC-1254 |
|
|
DC66650 |
CP-LC-0729 |
Lipid CP-LC-0729, an ionizable cationic amino lipid synthesized from homocysteine—a naturally occurring amino acid—has been shown to exhibit superior efficacy in the delivery and subsequent protein expression of various RNA modalities, including messenger RNA (mRNA), circular RNA (cRNA), and self-amplifying RNA (saRNA) in vivo. Importantly, CP-LC-0729 demonstrates an exemplary safety profile, with no observable toxicological effects in preclinical studies.
Comparative analyses reveal that CP-LC-0729 significantly surpasses MC3, a widely utilized benchmark lipid nanoparticle formulation, in terms of protein expression efficiency. Specifically, CP-LC-0729 achieves a striking 32-fold enhancement in protein expression within lung tissue relative to MC3, underscoring its pronounced tissue selectivity and targeting efficacy for pulmonary applications. These findings suggest that CP-LC-0729 represents a highly promising candidate for the development of RNA-based therapeutics, particularly in the context of lung-targeted delivery systems, where its combination of high efficiency and low toxicity offers significant translational potential. |
|
DC66651 |
CP-LC-0743 |
Lipid CP-LC-0743 is an ionizable cationic amino lipid derived from homocysteine, a naturally occurring amino acid. This lipid has demonstrated an efficient delivery and high protein expression of different kinds of RNA (mRNA, cRNA and saRNA) in vivo, with no signs of toxicity. |
|
DC66652 |
CP-LC-0867 |
|
|
DC66653 |
C9-200 |
C9-200 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNPs).1 LNPs containing C9-200 and encapsulating mRNA encoding erythropoietin (EPO) increase serum EPO levels in mice. LNPs containing C9-200 and encapsulating mRNA encoding the Cas9 nuclease and small-guide RNA (sgRNA) targeting transthyretin (TTR) induce 3-fold higher hepatic insertion and deletion (indel) formation than LNPs containing C12-200 (Item No. 36699) and encapsulating mRNA encoding Cas9 in mice. |
|
DC66654 |
Lipid N2-3L |
|
|
DC66655 |
YHS-12 |
YHS-12 is an ionizable cationic lipid (pKa = 6.506) that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of siRNA and mRNA in vitro and in vivo.1 LNPs containing YHS-12 and the macrophage targeting peptide CRVLRSGSC and encapsulating mRNA encoding chimeric antigen receptor targeting methicillin-resistant S. aureus (MRSA) and siRNA targeting caspase-11 increase the phagocytosis rate of MRSA in RAW 264.7 macrophages and primary mouse bone marrow-derived macrophages (BMDMs). Intravenous administration of these LNPs decreases blood bacterial burden and increases survival in a model of sepsis using cyclophosphamide-induced immunosuppressed mice. |
|
DC60662 |
Si6-C14b |
|
|
DC60663 |
Si5-N14
Featured
|
Si5-N14 is a lipid-based molecule engineered with siloxane groups, designed specifically for efficient mRNA delivery to the lungs. The incorporation of siloxane units boosts the cellular uptake of mRNA-loaded lipid nanoparticles (LNPs) and enhances their ability to escape from endosomes. These properties significantly increase the overall effectiveness of mRNA delivery, making Si5-N14 a promising tool for targeted therapeutic applications. |
|
DC60664 |
Si12-C10 |
|
|
DC60670 |
CL4F11-ζ-2 |
|
|
DC60671 |
THP1 |
THP1 is a tetrahydropyrimidine ionizable lipid for mRNA delivery. THP1 demonstrates higher transfection efficiency comparable to DLin-MC3-DMA (MC3). THP1 LNPs also demonstrates the ability to edit genes in specific liver tissues in a tdTomato transgenic mouse model. |
|
DC60673 |
(+)CP-LC-0729 |
|
|
DC60683 |
Lipid-168
Featured
|
Lipid-168, an ionizable lipid from Library A, features a diethylamino headgroup and optimized hydrophobic tail, enabling efficient mRNA delivery to bone marrow (BM) cells via protein corona-mediated targeting (e.g., albumin, fibronectin). It exhibits a pKa of ~6.5, facilitating endosomal escape, and achieves >90% mRNA encapsulation efficiency. LNPs formulated with Lipid-168 demonstrated 48.5% editing efficiency in BM cells after dual dosing in vivo, with reduced hepatic off-targeting through miR-122T incorporation. Cryo-EM confirmed uniform nanoparticle morphology (80-90 nm). Safety assessments showed transient cytokine spikes without sustained immunogenicity. |
|
DC60684 |
Lipid I97 |
|
|
DC60685 |
313O13 |
|
|
DC60686 |
313oi10 |
|
|
DC99010 |
CAPSTAN Lipid A-11
Featured
|
Compound A-11 (Lipid A11) is a novel ionizable cationic lipid for used for tLNP(targeting antibody LNP) targeting to T cell,with pKa range 6-7, high encapsulation efficiency and high T cell transfection, compared to benchmark ATX-126 and other lipids. |
|
DC67109 |
Fluorescent-SM102
Featured
|
|
|
DC67110 |
DOTMA |
DOTMA is a cationic lipid that has been used as a non-viral vector for gene therapy. DOTMA is used as a component of liposomes to encapsulate siRNA, microRNA, and oligonucleotides and for in vitro gene transfection. DOTMA promotes effective interaction between liposomes and cell membranes by inducing positive charge on the liposomes. DOTMA showed good gene transfection effect both in vitro and in vivo. |
|
DC67116 |
80-O14B |
|
|
DC67117 |
113-N16B
Featured
|
113-N16B is an ionizable cationic lipid used for the generation of lipid nanoparticles (LNPs). 113-N16B delivers mRNA preferentially to pulmonary endothelial cells. |
|
DC67118 |
PNI 132 |
|
|